

We Claim:

1. A combination comprising an anti-CD19 antibody and a BCL-2 inhibitor, for use in the treatment of a patient suffering from non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or small lymphocytic lymphoma, wherein said anti-CD19 antibody is administered at least 7 days prior to the first administration of said BCL-2 inhibitor.
2. A combination according to claim 1, wherein the anti-CD19 antibody is administered weekly, bi-weekly or monthly after a first administration on Day 1 and wherein the BCL-2 inhibitor is administered for the first time on Day 8.
3. A combination according to any one of the preceding claims, wherein the anti-CD19 antibody after a first administration on Day 1 is administered weekly for the first 3 months.
4. A combination according to claim 3, wherein the anti-CD19 antibody after a first administration on Day 1 is administered weekly for the first 3 months and bi-weekly for at least the next 3 months.
5. A combination according to claim 4, wherein the anti-CD19 antibody after a first administration on Day 1 is administered weekly for the first 3 months, bi-weekly for the next 3 months and monthly thereafter.
6. A combination according to any one of the preceding claims, wherein there is an additional dosing of the anti-CD19 antibody on Day 4.
7. A combination according to any one of the preceding claims, wherein the BCL-2 inhibitor is administered for the first time on Day 8 with a starting dose of 20mg followed by a weekly ramp-up dosing of 50mg, 100mg, 200mg and 400mg followed by a daily dosing of 400mg.

8. A combination according to any one of the preceding claims, wherein said anti-CD19 antibody and said BCL-2 inhibitor are administered separately.
9. A combination according to any one of the preceding claims, wherein said BCL-2 inhibitor is venetoclax.
10. A combination according to any one of the preceding claims, wherein the anti-CD19 antibody comprises an HCDR1 region comprising sequence SYVMH (SEQ ID NO: 1), an HCDR2 region comprising sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region comprising sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region comprising sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region comprising sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region comprising sequence MQHLEYPIT (SEQ ID NO: 6)
11. A combination according to claim 9, wherein the anti-CD19 antibody comprises a variable heavy chain comprising the sequence
EVQLVESGGGLVKPGGSLKLSAASGYTFTSYVMHWVRQAPGKGLEWIGYINPYNDGTKY
NEKFQGRVTISSDKSISTAYMELSSLRSEDAMYYCARGTYYYGTRVFDYWGGQTLTVSS
(SEQ ID NO: 10)
and a variable light chain of the sequence
DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYRMSNLNS
GVPDRFSGSGSGTEFTLTISLEPEDFAVYYCMQHLEYPITFGAGTKLEIK (SEQ ID NO: 11).
12. A combination according to any of claims 9 or 10, wherein the anti-CD19 antibody comprises a heavy chain constant domain comprising the sequence
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
LYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPDV
FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFR
VVSFLTIVVHQDWLNGKEYKCKVSNKALPAAPEEKTISKTKGQPREPQVYTLPPSREEMTKNQ
VSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPMLDSDGSFFLYSKLTVDKSRWQQGNV
FSCSVMHLEAHNHYTQKSLSLSPGK (SEQ ID NO: 12).

13. A combination according to any of claims 10 to 12, wherein the anti-CD19 antibody comprises a light chain constant domain comprising the sequence

RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDS
KD STYLSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC. (SEQ ID NO: 13)

14. A combination according to any of claims 10 to 13, wherein the anti-CD19 antibody is administered in a concentration of 12mg/kg.

15. A combination according to any one of the preceding claims for use in the treatment of chronic lymphocytic leukemia, small lymphocytic lymphoma or non-Hodgkin's lymphoma, wherein the non-Hodgkin's lymphoma is selected from the group consisting of follicular lymphoma, small lymphocytic lymphoma, mucosa-associated lymphoid tissue, marginal zone, diffuse large B cell, Burkitt's, and mantle cell.